[ad_1]
Clinical trials of the COVID-19 vaccine being developed by the University of Oxford and AstraZeneca, one of the most promising in the world, will resume after being interrupted.
(Context: Due to possible adverse reaction, Oxford vaccine tests suspended)
A statement released this Saturday by the university indicated that clinical tests of the substance, called ChAdOx1 nCoV-19, will resume in the United Kingdom after a pause arranged as a precautionary measure.
This possible vaccine is in the final stages of clinical trials before receiving authorization from regulatory bodies to proceed with immunizing the population.
(We recommend: How much would the vaccine made by the University of Oxford cost?)
At the end of August, the European Union closed a “first contract” with AstraZeneca that guaranteed it access to 300 million doses of the vaccine, therefore the suspension of trials was a serious concern in Europe and around the world.
In the statement, the university indicated that some 18,000 people have received this study vaccine as part of clinical trials and that, in tests as extensive as this, it is expected that some participant may feel bad.
“Each case must be carefully evaluated to confirm the safety of the vaccine,” added the Oxford statement, which has not specified the date of resumption of the trials.
The tests will begin again after the completion of the independent review process and after the approval of the Regulatory Authority for Medicines for Health (MHRA), regulator of the pharmaceutical sector.
“We cannot disclose medical information about the disease (of the volunteer) for reasons of confidentiality of the participant,” they explained. “We are committed to the safety of our participants and the highest level of conduct in our studies and will closely monitor dose safety.”
(You could read: What do the country’s laboratories propose to the vaccine against covid-19?)
In August, the governments of Argentina and Mexico, as well as the Mexican Slim Foundation, reached an agreement with AstraZeneca and the University of Oxford to manufacture the vaccine for their countries and then distribute it to the rest of Latin America, except Brazil.
The president of Argentina, Alberto Fernández, reported last month that the goal was to produce between 150 and 250 million doses that would be available at affordable prices, with an individual cost of between 3 and 4 dollars.
The European Union’s contract with the pharmaceutical company was signed on behalf of the member states and the doses that it would distribute proportionally according to the population of each country.
(Also: EU reserves 225 million doses of potential vaccine against covid-19)
The vaccine project is in the final stages after the results of the first trials, published last July in the British medical journal The Lancet, indicated that it was safe and “trains” the immune system against the coronavirus.
AstraZeneca CEO Pascal Soriot indicated last Thursday that the vaccine could still be available by the end of the year despite the interruption of trials and stressed that pauses in clinical trials of this type are not unusual because of ” adverse events”.
In the world there are more than 30 vaccines that are being tested in humans and nine of them in the final stages. The idea is to contain the coronavirus pandemic, which has already caused more than 28 million cases, more than 900,000 deaths and is hurting economies.
EFE
–
